|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:administration_schedule
|
two doses
|
|
gptkbp:benefits
|
rapid production
|
|
gptkbp:clinical_trial
|
gptkb:various_countries
Phase 1
healthy adults
pending
Phase 2
|
|
gptkbp:collaboration
|
various research institutions
|
|
gptkbp:collaborations
|
academic institutions
|
|
gptkbp:community_health
|
potential to reduce influenza cases
|
|
gptkbp:developed_by
|
gptkb:Cure_Vac_AG
|
|
gptkbp:funding
|
public and private investments
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cure Vac's m RNA vaccine for influenza
|
|
gptkbp:immune_response
|
B-cell response
T-cell response
|
|
gptkbp:is_effective_against
|
under investigation
|
|
gptkbp:is_vulnerable_to
|
gptkb:educational_campaigns
ongoing
government grants
continuous monitoring
to be determined
ongoing clinical trials
refrigerated conditions
lipid nanoparticle
preventive vaccine
global distribution plans
m RNA technology advancement
requires further studies
|
|
gptkbp:manufacturing_process
|
gptkb:biotechnology
|
|
gptkbp:outcome
|
safety
immunogenicity
|
|
gptkbp:partnerships
|
pharmaceutical companies
|
|
gptkbp:regulatory_compliance
|
not approved
|
|
gptkbp:research_focus
|
influenza prevention
|
|
gptkbp:research_phase
|
preclinical studies
|
|
gptkbp:route_of_administration
|
intramuscular injection
|
|
gptkbp:safety_features
|
under evaluation
|
|
gptkbp:shipping_options
|
lipid nanoparticles
|
|
gptkbp:target_audience
|
general population
|
|
gptkbp:targets
|
gptkb:virus
|
|
gptkbp:technology
|
m RNA technology
|
|
gptkbp:vaccine_clinical_trial_phases
|
multiple phases planned
|
|
gptkbp:vaccine_development_challenges
|
scientific and logistical challenges
|
|
gptkbp:vaccine_future_prospects
|
potential for pandemic response
|
|
gptkbp:vaccine_market_potential
|
high demand for influenza vaccines
|
|
gptkbp:vaccine_production_capacity
|
scalable production
|
|
gptkbp:vaccine_research_challenges
|
regulatory hurdles
|
|
gptkbp:vaccine_research_collaborators
|
international research teams
|
|
gptkbp:vaccine_research_funding_sources
|
private investors
|
|
gptkbp:vaccine_research_goals
|
improve vaccine response
|
|
gptkbp:vaccine_shelf_life
|
limited shelf life
|
|
gptkbp:vaccine_target_strains
|
seasonal influenza strains
|
|
gptkbp:bfsParent
|
gptkb:Cure_Vac_AG
|
|
gptkbp:bfsLayer
|
5
|